Pediatric Cardiology

, Volume 28, Issue 4, pp 250–254 | Cite as

Increased Incidence of Idiopathic Persistent Pulmonary Hypertension in Down Syndrome Neonates

  • C. L. Cua
  • A. Blankenship
  • A. L. North
  • J. Hayes
  • L. D. Nelin
ORIGINAL ARTICLE

Abstract

Down syndrome (DS) patients have an increased risk of developing pulmonary hypertension later in life compared to age-matched controls. The goal of this study was to determine if the incidence of persistent pulmonary hypertension of the newborn (PPHN) is also higher in neonatal DS patients compared to the general population. A retrospective chart review of DS patients admitted during a 3-year period to the neonatal intensive care unit was performed. DS patients with meconium aspiration syndrome, pulmonary infections, or pulmonary space-occupying lesions were excluded. DS patients were divided into four groups based on treatment and consisted of no intervention (A), supplemental oxygen (B,) mechanical ventilation use (C), and inhaled nitric oxide administration (D). Group D was defined as having PPHN. z test of the difference between sample and known population, chi-square, t-test, and analysis of variance with Tukey adjusted post hoc test were used for analysis. p < 0.05 was considered significant. A total of 58 patients met inclusion criteria. Twenty-four DS patients were in group A, 17 in group B, 10 in group C, and 7 in group D. There was no difference between the four groups for gender (males: 10, 5, 5, and 5, respectively), gestational age (36.4, 38.2, 36.4, and 36.4 weeks, respectively), weight (2.8, 3.0, 2.4, and 3.0 kg, respectively), or the presence of congenital heart defects (17, 10, 6, and 1, respectively). The estimated number of DS patients born in the state of Ohio during this period was 598; therefore, the incidence of PPHN in DS was 1.2%. The reported incidence of PPHN is 0.1%. The Reported incidence of PPHN was significantly lower versus the incidence of PPHN in DS (z = 2.7, p = 0.007). It was concluded that DS patients have an increased incidence of PPHN compared to historical controls regardless of baseline demographics.

Keywords

Down syndrome Pulmonary hypertension Neonate 

References

  1. 1.
    Abraham WT, Raynolds MV, Badesch DB, et al. (2003) Angiotensin-converting enzyme DD genotype in patients with primary pulmonary hypertension: increased frequency and association with preserved haemodynamics. J Renin Angiotensin Aldosterone Syst 4:27–30PubMedCrossRefGoogle Scholar
  2. 2.
    Abraham WT, Raynolds MV, Gottschall B, et al. (1995) Importance of angiotensin-converting enzyme in pulmonary hypertension. Cardiology 86(Suppl 1):9–15PubMedCrossRefGoogle Scholar
  3. 3.
    Ahsan A, Ram R, Baig MA, Pasha MA (2004) ACE I allele and eNOS G allele crosstalk may have a role in chronic obstructive pulmonary disease. Clin Biochem 37:1037–1040PubMedCrossRefGoogle Scholar
  4. 4.
    Cannon BC, Feltes TF, Fraley JK, et al. (2005) Nitric oxide in the evaluation of congenital heart disease with pulmonary hypertension: factors related to nitric oxide response. Pediatr Cardiol 26:565–569PubMedCrossRefGoogle Scholar
  5. 5.
    Cappelli-Bigazzi M, Santoro G, Battaglia C, et al. (2004) Endothelial cell function in patients with Down’s syndrome. Am J Cardiol 94:392–395PubMedCrossRefGoogle Scholar
  6. 6.
    Chi TPLKJ (1975) The pulmonary vascular bed in children with Down syndrome. J Pediatr 86:533–538CrossRefGoogle Scholar
  7. 7.
    Clapp S, Perry BL, Farooki ZQ, et al. (1990) Down’s syndrome, complete atrioventricular canal, and pulmonary vascular obstructive disease. J Thorac Cardiovasc Surg 100:115–121PubMedGoogle Scholar
  8. 8.
    Cooney TP, Thurlbeck WM (1982) Pulmonary hypoplasia in Down’s syndrome. N Engl J Med 307:1170–1173PubMedCrossRefGoogle Scholar
  9. 9.
    Hasegawa N, Oshima M, Kawakami H, Hirano H (1990) Changes in pulmonary tissue of patients with congenital heart disease and Down syndrome: a morphological and histochemical study. Acta Paediatr Jpn 32:60–66PubMedGoogle Scholar
  10. 10.
    Improved national prevalence estimates for 18 selected major birth defects—United States, 1999–2001 (2006) Morbid Mortal Weekly Rep 54:1301–1305Google Scholar
  11. 11.
    Jugdutt BI, Menon V (2004) AT1 receptor blockade limits myocardial injury and upregulates AT2 receptors during reperfused myocardial infarction. Mol Cell Biochem 260:111–118PubMedCrossRefGoogle Scholar
  12. 12.
    Kawai T, Wada Y, Enmoto T, et al. (1995) Comparison of hemodynamic data before and after corrective surgery for Down’s syndrome and ventricular septal defect. Heart Vessels 10:154–157PubMedCrossRefGoogle Scholar
  13. 13.
    Kunnas TA, Lehtimaki T, Laaksonen R, et al. (2002) Endothelial nitric oxide synthase genotype modulates the improvement of coronary blood flow by pravastatin: a placebo-controlled PET study. J Mol Med 80:802–807PubMedCrossRefGoogle Scholar
  14. 14.
    Lefaivre JF, Cohen SR, Burstein FD, et al. (1997) Down syndrome: identification and surgical management of obstructive sleep apnea. Plast Reconstr Surg 99:629–637PubMedCrossRefGoogle Scholar
  15. 15.
    Levine OR, Simpser M (1982) Alveolar hypoventilation and cor pulmonale associated with chronic airway obstruction in infants with Down syndrome. Clin Pediatr (Philadelphia) 21:25–29Google Scholar
  16. 16.
    Lindberg L, Olsson AK, Jogi P, Jonmarker C (2002) How common is severe pulmonary hypertension after pediatric cardiac surgery? J Thorac Cardiovasc Surg 123:1155–1163PubMedCrossRefGoogle Scholar
  17. 17.
    Machado RD, Pauciulo MW, Thomson JR, et al. (2001) BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension. Am J Hum Genet 68:92–102PubMedCrossRefGoogle Scholar
  18. 18.
    Mettimano M, Romano-Spica V, Ianni A, et al. (2002) AGT and AT1R gene polymorphism in hypertensive heart disease. Int J Clin Pract 56:574–577PubMedGoogle Scholar
  19. 19.
    Roberts KE, McElroy JJ, Wong WP, et al. (2004) BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 24:371–374PubMedCrossRefGoogle Scholar
  20. 20.
    Rowland TW, Nordstrom LG, Bean MS, Burkhardt H (1981) Chronic upper airway obstruction and pulmonary hypertension in Down’s syndrome. Am J Dis Child 135:1050–1052PubMedGoogle Scholar
  21. 21.
    Runo JR, Vnencak-Jones CL, Prince M, et al. (2003) Pulmonary veno-occlusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 167:889–894PubMedCrossRefGoogle Scholar
  22. 22.
    Shah PS, Hellmann J, Adatia I (2004) Clinical characteristics and follow up of Down syndrome infants without congenital heart disease who presented with persistent pulmonary hypertension of newborn. J Perinat Med 32:168–170PubMedCrossRefGoogle Scholar
  23. 23.
    Shimasaki Y, Yasue H, Yoshimura M, et al. (1998) Association of the missense Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 31:1506–1510PubMedCrossRefGoogle Scholar
  24. 24.
    Suzuki K, Yamaki S, Mimori S, et al. (2000) Pulmonary vascular disease in Down’s syndrome with complete atrioventricular septal defect. Am J Cardiol 86:434–437PubMedCrossRefGoogle Scholar
  25. 25.
    Walsh-Sukys MC, Tyson JE, Wright LL, et al. (2000) Persistent pulmonary hypertension of the newborn in the era before nitric oxide: practice variation and outcomes. Pediatrics 105:14–20PubMedCrossRefGoogle Scholar
  26. 26.
    Wilson SK, Hutchins GM, Neill CA (1979) Hypertensive pulmonary vascular disease in Down syndrome. J Pediatr 95: 722–726PubMedCrossRefGoogle Scholar
  27. 27.
    Wolff B, Grabe HJ, Schluter C, et al. (2005) Endothelial nitric oxide synthase Glu298Asp gene polymorphism, blood pressure and hypertension in a general population sample. J Hypertens 23:1361–1366PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • C. L. Cua
    • 1
  • A. Blankenship
    • 1
  • A. L. North
    • 1
  • J. Hayes
    • 1
  • L. D. Nelin
    • 1
  1. 1.Department of Pediatrics, Section of CardiologyColumbus Children’s Hospital and The Ohio State UniversityColumbusUSA

Personalised recommendations